MX373324B - Compuestos piridínicos de pladienolida y métodos de uso. - Google Patents

Compuestos piridínicos de pladienolida y métodos de uso.

Info

Publication number
MX373324B
MX373324B MX2016014997A MX2016014997A MX373324B MX 373324 B MX373324 B MX 373324B MX 2016014997 A MX2016014997 A MX 2016014997A MX 2016014997 A MX2016014997 A MX 2016014997A MX 373324 B MX373324 B MX 373324B
Authority
MX
Mexico
Prior art keywords
compounds
methods
pyridinic
pladienolide
useful
Prior art date
Application number
MX2016014997A
Other languages
English (en)
Other versions
MX2016014997A (es
Inventor
Baudouin Gerard
Betty Chan
Ermira Pazolli
Eunice Sun Park
Gregg F Keaney
Guo Zhu Zheng
John Wang
Kazunobu Kira
Kenzo Arai
Kian Huat Lim
Lihua Yu
Masayuki Miyano
Michael P Thomas
Nicholas C Gearhart
Norio Murai
Parcharee Tivitmahaisoon
Peter G Smith
Regina Kanada SONOBE
Satoshi Nagao
Silvia Buonamici
Sudeep Prajapati
Xiang Liu
Yoshihiko Kotake
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373324(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2016014997A publication Critical patent/MX2016014997A/es
Publication of MX373324B publication Critical patent/MX373324B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee compuestos piridínicos de pladienolida novedosos, composiciones farmacéuticas que los contienen, y métodos para usar los compuestos como agentes terapéuticos. Estos compuestos pueden ser útiles en el tratamiento del cáncer, particularmente cánceres en los cuales se conoce que son útiles los agentes que están dirigidos al spliceosoma y mutaciones en el mismo.
MX2016014997A 2014-05-15 2015-05-13 Compuestos piridínicos de pladienolida y métodos de uso. MX373324B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
PCT/US2015/030464 WO2015175594A1 (en) 2014-05-15 2015-05-13 Pladienolide pyridine compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2016014997A MX2016014997A (es) 2017-06-29
MX373324B true MX373324B (es) 2020-05-04

Family

ID=53284528

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004476A MX388580B (es) 2014-05-15 2015-05-13 Compuestos piridinicos de pladienolida y metodos de uso
MX2016014997A MX373324B (es) 2014-05-15 2015-05-13 Compuestos piridínicos de pladienolida y métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004476A MX388580B (es) 2014-05-15 2015-05-13 Compuestos piridinicos de pladienolida y metodos de uso

Country Status (36)

Country Link
US (1) US9481669B2 (es)
EP (2) EP3143016B1 (es)
JP (1) JP6067943B1 (es)
KR (2) KR102146726B1 (es)
CN (1) CN107074827B (es)
AR (1) AR100431A1 (es)
AU (1) AU2015259237B2 (es)
BR (1) BR112016026638B1 (es)
CA (1) CA2947754C (es)
CL (1) CL2016002835A1 (es)
CY (1) CY1121550T1 (es)
DK (1) DK3143016T3 (es)
ES (1) ES2712401T3 (es)
HR (1) HRP20190432T1 (es)
HU (1) HUE041838T2 (es)
IL (1) IL248529B (es)
JO (1) JO3668B1 (es)
LT (1) LT3143016T (es)
MA (1) MA39915B1 (es)
ME (1) ME03417B (es)
MX (2) MX388580B (es)
MY (1) MY195081A (es)
PE (1) PE20170384A1 (es)
PH (1) PH12016502249B1 (es)
PL (1) PL3143016T3 (es)
PT (1) PT3143016T (es)
RS (1) RS58400B1 (es)
RU (1) RU2707730C2 (es)
SG (1) SG11201609693XA (es)
SI (1) SI3143016T1 (es)
SM (1) SMT201900158T1 (es)
TR (1) TR201902328T4 (es)
TW (1) TWI634115B (es)
UA (1) UA119458C2 (es)
WO (1) WO2015175594A1 (es)
ZA (1) ZA201607354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040526A2 (en) 2015-09-01 2017-03-09 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
BR112018009995B1 (pt) * 2015-11-18 2024-04-30 Eisai R&D Management Co., Ltd Forma cristalina, composição farmacêutica, e, uso da forma cristalina
US20200190593A1 (en) 2017-03-15 2020-06-18 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
MX2020004179A (es) * 2017-10-31 2020-08-03 Eisai R&D Man Co Ltd Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
TWI863903B (zh) * 2018-04-09 2024-12-01 日商衛材R&D企管股份有限公司 特定普拉二烯內酯化合物及其使用方法
IL304988B2 (en) 2018-04-12 2025-02-01 Eisai R&D Man Co Ltd History of Palladianolide as spliceosome-targeting agents for cancer therapy
WO2019232449A1 (en) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
JP7346466B2 (ja) 2018-06-01 2023-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬の使用方法
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
TWI901692B (zh) * 2020-06-05 2025-10-21 日商衛材R&D企管股份有限公司 抗ｂｃｍａ抗體-藥物軛合物及其使用方法
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
EP4361136A4 (en) * 2021-06-18 2025-08-13 Univ Cordoba Compound for the treatment of glioblastoma
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2024101298A1 (ja) 2022-11-07 2024-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド化合物の製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
CA2494536C (en) 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
CA2546614A1 (en) 2003-11-27 2005-06-09 Mercian Corporation Dna participating in hydroxylation of macrolide compound
ES2345493T3 (es) 2003-11-28 2010-09-24 Kanagawa Academy Of Science And Technology Metodo de deteccion de cancer de higado, diagnostico de cancer de higado y remedio para el cancer.
EP1764592A4 (en) 2004-07-02 2009-08-19 Plus One Techno & Co Ltd COMBINED WEIGHING APPARATUS
US8008049B2 (en) 2004-07-20 2011-08-30 Eisai R&D Management Co., Ltd. DNA coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
CN102010403A (zh) 2005-10-13 2011-04-13 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
US20100021918A1 (en) * 2007-03-05 2010-01-28 Eisai R&D Management Co., Ltd. Method for assaying action of antitumor agent using splicing defects as index
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
EP3143016A1 (en) 2017-03-22
EP3514154A1 (en) 2019-07-24
BR112016026638B1 (pt) 2022-08-02
ME03417B (me) 2020-01-20
PL3143016T3 (pl) 2019-04-30
NZ725603A (en) 2023-11-24
AU2015259237A1 (en) 2016-11-10
PH12016502249A1 (en) 2017-02-06
EP3143016B1 (en) 2018-12-12
HRP20190432T1 (hr) 2019-04-19
CY1121550T1 (el) 2020-05-29
KR20160082256A (ko) 2016-07-08
MA39915B1 (fr) 2019-05-31
JP2017505282A (ja) 2017-02-16
JO3668B1 (ar) 2020-08-27
KR20170021899A (ko) 2017-02-28
AU2015259237B2 (en) 2019-08-15
CN107074827B (zh) 2020-12-18
MX2016014997A (es) 2017-06-29
PE20170384A1 (es) 2017-05-11
DK3143016T3 (en) 2019-04-08
US9481669B2 (en) 2016-11-01
RS58400B1 (sr) 2019-04-30
TW201625596A (zh) 2016-07-16
HUE041838T2 (hu) 2019-05-28
TR201902328T4 (tr) 2019-03-21
RU2016148887A (ru) 2018-06-18
WO2015175594A1 (en) 2015-11-19
CN107074827A (zh) 2017-08-18
MX2020004476A (es) 2021-12-08
NZ764190A (en) 2023-11-24
LT3143016T (lt) 2019-06-10
AR100431A1 (es) 2016-10-05
MA39915A (fr) 2017-03-22
CA2947754C (en) 2024-01-02
IL248529B (en) 2019-11-28
RU2707730C2 (ru) 2019-11-29
SG11201609693XA (en) 2016-12-29
ES2712401T3 (es) 2019-05-13
US20150329528A1 (en) 2015-11-19
KR101710318B9 (ko) 2026-02-06
UA119458C2 (uk) 2019-06-25
PH12016502249B1 (en) 2023-12-13
EP3514154B1 (en) 2022-08-03
CA2947754A1 (en) 2015-11-19
RU2016148887A3 (es) 2018-12-11
SMT201900158T1 (it) 2019-05-10
TWI634115B (zh) 2018-09-01
BR112016026638A2 (es) 2017-08-15
SI3143016T1 (sl) 2019-04-30
MX388580B (es) 2025-03-20
JP6067943B1 (ja) 2017-01-25
CL2016002835A1 (es) 2017-04-17
ZA201607354B (en) 2018-05-30
RU2019124012A (ru) 2019-08-12
IL248529A0 (en) 2016-12-29
KR101710318B1 (ko) 2017-02-24
KR102146726B9 (ko) 2026-02-05
MY195081A (en) 2023-01-09
PT3143016T (pt) 2019-02-27
KR102146726B1 (ko) 2020-08-21

Similar Documents

Publication Publication Date Title
MX373324B (es) Compuestos piridínicos de pladienolida y métodos de uso.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201890754A1 (ru) Соединения и способы их применения
TW201613648A (en) Compounds and compositions for immunotherapy
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
PH12016501791A1 (en) Muscarinic receptor agonists
EA201590997A1 (ru) Соединения и способы их применения
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX392475B (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
PH12016501838A1 (en) Compounds and their methods of use
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
BR112015029216A2 (pt) tratamento de vasculopatia coroidal polipoidal

Legal Events

Date Code Title Description
FG Grant or registration